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PURPOSE: This study evaluated the efficacy and safety of adjuvant chemotherapy with the docetaxel plus cisplatin
and 5-fluorouracil (5-FU) (DCF) regimen in patients with gastric cancer. PATIENTS AND METHODS: Thirty-two
patients with gastric or gastroesophageal junction cancer were enrolled in this study after undergoing radical
resection. The patients received the following chemotherapy: docetaxel (60 mg/m2) on day 1, cisplatin (12 mg/m2
per day) on days 1 to 5, and 5-FU (2500 mg/m2) continuous infusion for 120 hours, repeated every 3 weeks for
six cycles. The primary end point was disease-free survival (DFS). RESULTS: The median DFS was 17.0 months.
The 1-year DFS was 72%, and the 2-year DFS was 37.5%. The median overall survival was 28.0 months. Using
univariate analysis, the technique of lymph node dissection was a predictor for postoperative relapse. The median
DFS was 15.0 months in the D1 group and 18.0 months in the D2 group (P = .043). The most frequent grade 3/4
adverse events were neutropenia (56.25%), diarrhea (9.38%), nausea (6.25%), and vomiting (6.25%); 12.5% of
patients developed febrile neutropenia. There were no chemotherapy-related deaths. CONCLUSIONS: The
modified DCF regimen is an effective adjuvant chemotherapy in gastric cancer. Hematologic toxicity was frequent
but manageable. This regimen merits further investigation.
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Worldwide, gastric cancer is the fourth most common cancer and the
second most common cause of cancer deaths [1]. China has a high
incidence of gastric carcinoma. The incidence of gastric cancer has
been increasing in China. In 2008, Chinese cases of gastric cancer
accounted for more than 42% of the worldwide incidence [2].
According to the Chinese National Office for Cancer Prevention and
Control (Beijing, China), gastric cancer incidence is still the most
common cause of cancer death in China, and gastric cancer mortality
accounted for nearly one fourth of all cancer deaths [3].
Complete surgical eradication of a gastric tumor represents the best
chance for long-term survival. Nevertheless, nearly half of patients
will develop recurrence or metastasis in a short period after radical
surgery. In the United States, adjuvant chemoradiotherapy is the
standard treatment for resectable gastric cancer. In much of Europe,
neoadjuvant chemotherapy has become the preferred treatment
strategy. However, the standard of care in Asia is still adjuvant
chemotherapy. Many randomized trials have compared adjuvant
systemic chemotherapy to surgery alone, with variable results. Some
meta-analyses have shown that adjuvant chemotherapy has asignificant survival benefit [4]. To date, outcomes of adjuvant
treatment in gastric cancer remain disappointing. For locally
advanced gastric cancer (AGC), the 5-year survival rate reported in
the Japanese literature is approximately 50% [5] and is only 8% to
20% in the United States [6].
With the development of new chemotherapy agents, gastric cancer
survival has improved. However, the question of which regimen is most
effective for gastric cancer remains unresolved. This study was a single-
center prospective phase II trial. In this study, we evaluated the efficacy
and safety of docetaxel plus cisplatin and 5-fluorouracil (5-FU) (DCF)
regimen as adjuvant chemotherapy for gastric cancer.
Table 1. Patient Characteristics.
Characteristics n %
Age
Median (yr) 50
Range (yr) 24-68
Sex
Male 23 71.9%
Female 9 28.1%
Primary site
GEJ 6 18.8%
Fundus 1 3.1%
Body 6 18.8%
Antrum 19 59.4%
Lymphadenectomy
D1 10 31.3%
D2 22 68.8%
Histology
Andenocarcinoma 30 93.8%
Signet-ring cell carcinoma 2 6.3%
Differentiation
Moderate 5 15.6%
Low 27 84.4%
TNM stage (AJCC 7.0)
I 2 6.3%
II 8 25.0%
III 22 68.8%
GEJ, gastroesophageal junction.
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Patients
Eligibility criteria for this study included the following: age of 18
years or older, histologically confirmed gastric or gastroesophageal
junction adenocarcinoma, complete resection of the tumor, enroll-
ment between 3 and 6 weeks after radical resection, American Joint
Committee on Cancer (AJCC) (version 7.0) stage of IB to IIIC, no
prior treatment for gastric cancer, Eastern Cooperative Oncology
Group performance status of 0 to 1, and adequate hepatic, renal, and
hematologic function [as indicated by serum bilirubin ≤1.5× upper
limit of normal (ULN), serum aspartate aminotransferase ≤2.5×
ULN, alkaline phosphatase ≤2.5× ULN, creatinine ≤1.5× ULN,
hemoglobin ≥80 g/l, platelets ≥75×109 per liter, and absolute
neutrophil count ≥1.5×109 per liter]. Patients were ineligible if
distant metastases or severe/uncontrolled medical comorbidities were
present. Patients were enrolled after signing an informed consent
form that was approved by the Ethics Committee of Peking Union
Medical College Hospital.
Treatment
After undergoing gastrectomy, patients began postoperative
chemotherapy. The regimen consisted of docetaxel (60 mg/m2) on
day 1, cisplatin (12 mg/m2 per day) on days 1 to 5, and 5-FU (2500
mg/m2) continuous infusion for 120 hours. Chemotherapy was
repeated every 3 weeks for a total of six cycles.
Dose reductions or interruptions were allowed to manage
potentially serious or life-threatening adverse events. Full doses of
antineoplastic agents were given for the first cycle. If an episode of
grade 2 neutropenia, thrombocytopenia, or nonhematologic toxicity
was recorded, the treatment was delayed until the toxicity resolved to
baseline or grade 1. If grade 3 or 4 adverse events occurred,
subsequent doses of cytotoxic drugs were reduced to 75% of the
planned dose until the toxicity resolved to baseline or grade 1. After
dose reduction, if grade 3 or 4 toxicities still occurred, patients were
removed from the study.
Follow-Up
Postoperatively, all of the patients underwent a systematic baseline
assessment. Chest and abdominal computed tomography scan and
whole-body bone scan were required to exclude patients with
postoperative recurrence and/or distant metastasis. During and after
adjuvant chemotherapy, follow-up visits were required at 3-month
intervals for 2 years, then at 6-month intervals for 3 years, and yearly
thereafter. Follow-up consisted of a physical examination, a complete
blood count, liver function testing, and chest/abdominal computed
tomography scan as clinically indicated. If signs or symptoms
indicated a possible recurrence, further tests were then conducted to
verify whether the patient was disease free. The same assessment
paradigm was used for each patient.
Statistical Analysis
The primary end point of the study was disease-free survival (DFS).
Secondary end points were overall survival (OS) and toxicity. DFS
was defined as the time from enrollment to recurrence, second cancer,
or death from any cause, whichever came first. OS was defined as the
time from enrollment to death from any cause or to the last follow-up
visit. Patients who were still alive were censored on the date of the last
follow-up visit for the purposes of statistical analysis.Adverse events were graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse Events
(version 3.0) (Bethesda, MD). Adverse events were recorded during
chemotherapy and for 4 weeks after the last dose of study medication.
Statistical analyses were performed using SPSS version 17.0 (SPSS
Inc., Chicago, IL). Estimates of values were calculated using 95%
confidence intervals (CIs). DFS and OS were analyzed using the
Kaplan-Meier method. A P value of less than .05 was considered to be
statistically significant.
Results
Patient Characteristics
From November 2006 to June 2011, 32 patients with gastric
cancer were enrolled in this study. The median age was 50 years
(range = 24-68). The TNM stages according to the AJCC system
(version 7.0) were as follows: stage I, 2 patients (6.25%); stage II,
8 patients (25.0%); and stage III, 22 patients (68.75%). Table 1
shows details of the patients’ profiles.
Treatment
Surgical Procedures. All patients underwent radical surgery. Most of
the patients underwent a D2 lymphadenectomy (22 patients,
68.75%). D1 lymphadenectomy was performed in 10 patients
(31.25%).
Chemotherapy. All patients received adjuvant DCF chemotherapy
after radical resection. Twenty-four patients (75%) completed the
planned six cycles of treatment, and 8 patients (25%) stopped chemo-
therapy because of toxicity (n = 7) or disease progression (n = 1)
(Table 2). The median number of cycles received was 5.3 (range = 1-6).
Efficacy
Median follow-up was 29.8 months (range = 6.0-61.0). No
patients were lost to follow-up. Sixteen patients (50%) developed
local recurrence or metastases. The median DFS was 17.0 months
(95% CI = 13.7-20.3). In this study, the 1-year DFS rate was 72%,
Table 2. Reasons For Discontinuation Chemotherapy.
Received Cycles n % Major Reasons
1 1 3.2% G3 gastrointestinal effect
2 2 6.3% First patient: hypertension and arrhythmia
Second patient: change to XELOX because of medical condition
4 3 9.4% First patient: G2 bone marrow, GI, peripheral neuropathy
Second patient: G2 arrhythmia
Third patient: G2 neutropenia
5 2 6.3% First patient: GI toxicity
Second patient: PD
GI, gastrointestinal; PD, progressive disease.
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months (95% CI = 19.7-36.3), as shown in Figure 1.
Using univariate analysis, the technique of lymph node dissection
was a predictor for postoperative relapse. The median DFS was 15.0
months in the D1 group and 18.0 months in the D2 group (P =
.043), as shown in Figure 2A. No significant difference in DFS was
observed on subgroup analyses of other factors such as sex, age,
primary site, histology, differentiation, clinical stage, and cycles of
adjuvant chemotherapy received. The median DFS was 28 months in
stage I patients, 25.0 months in stage II patients, and 15.0 months in
stage III patients (P = .660), as shown in Figure 3A.
None of the factors analyzed were significant predictors of OS on
univariate analysis. The median OS was 23.0 months (95% CI =Figure 1. Median DFS and median OS for all patients. A) Median
DFS was 17.0 months. B) Median OS was 28.0 months.15.3-30.7) in the D1 group and 28.0 months (95% CI = 20.0-36.0)
in the D2 group (P = .786), as shown in Figure 2B. The median OS
was 29.0 months (95% CI = 26.2-31.8) in the stage II group and
22.3 months (95% CI = 19.5-25.1) in the stage III group (P = .983),
as presented in Figure 3B.
Toxicity
The most commonly reported adverse events of any grade were
neutropenia (90.6%), nausea (78.1%), vomiting (56.3%), and
anemia (53.1%). Most of these toxicities were mild. The only
grade 3/4 adverse event that occurred in more than 10% of patients
was neutropenia.
The most frequent hematologic adverse events were grade 3/4
neutropenia, which occurred in 18 patients (56.3%), and febrile
neutropenia, which developed in 4 patients (12.5%). The frequency
of anemia was high at 53.13%, but all of these toxicities were grade
1/2. Grade 1/2 thrombocytopenia was recorded in eight patients
(25.0%), but no grade 3/4 cases of thrombocytopenia occurred.
The most frequent grade 3/4 nonhematologic adverse events were
diarrhea (9.4%; n = 3), nausea (6.3%; n = 2), and vomiting (6.3%;
n = 2). Cases of peripheral neuropathy were all grade 1/2 (15.6%;
n = 5). There were no chemotherapy-related deaths (Table 3).
Discussion
Gastric cancer has a high risk of relapse and metastasis after radical
resection. Early clinical studies failed to confirm that adjuvant
chemotherapy prolongs survival. In 2009, a meta-analysis of 12
randomized clinical trials analyzed 3809 patients [7]. The hazard ratio
for OS was 0.78 (95% CI = 0.71-0.85) in favor of chemotherapy.
The most recently published meta-analysis evaluated data from 34
randomized trials that compared adjuvant systemic chemotherapy to
surgery alone and were conducted in both Asian and Western
populations [8]. The risk of death among patients receiving adjuvant
chemotherapy was reduced by 15% [hazard ratio (HR) = 0.85). To
date, two large-scale phase III clinical trials have demonstrated a
benefit of adjuvant chemotherapy in patients with gastric cancer who
underwent curative surgery with D2 lymphadenectomy. One was the
Japanese adjuvant chemotherapy trial of TS-1 for gastric cancer
(ACTS-GC) trial [9]. In the ACTS-GC trial, 1059 patients with stage
II or III gastric cancer who had undergone a D2 lymphadenectomy
were randomly assigned to 6 months of S-1 versus surgery alone. Five-
year OS was significantly better with S-1 (72% vs 61%). Another
study was the Asian multicenter capecitabine and oxaliplatin adjuvant
study in stomach cancer (CLASSIC) trial, in which 1035 patients
with stage II/III gastric cancer were randomly assigned to capecitabine
plus oxaliplatin (XELOX) or observation after a D2 gastrectomy [10].
Adjuvant chemotherapy was associated with a significant improve-
ment in 3-year DFS (74% vs 59%; HR = 0.56) and OS (78% vs
69%; HR = 0.66) [11].
The optimal adjuvant chemotherapy regimen has not yet been
established. There are several choices, including S-1 (used in the
ACTS-GC trial) [10], XELOX (used in the CLASSIC trial) [11],
capecitabine plus cisplatin (used in the adjuvant chemoradiation
therapy in stomach cancer trial) [12] or epirubicin, cisplatin, and
infused fluorouracil (used in the Medical Research Council Adjuvant
Gastric Infusional chemotherapy trial) [13]. However, it is unclear
which regimen is best or whether a superior alternative approach exists.
Docetaxel is a novel antitumor drug that promotes microtubule
assembly from tubulin dimers and inhibits the depolymerization of
Figure 2.Median DFS and median OS in the D1 and D2 groups. A) Median DFS in the D1 group was 15.0 months and 18.0 months in the
D2 group (P = .043). B) Median OS in the D1 group was 23.0 months and 28.0 months in the D2 group (P = .786). D1 group, D1
lymphadenectomy; D2 group, D2 lymphadenectomy.
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the inhibition of DNA, RNA, and protein synthesis [14]. The efficacy
of docetaxel monotherapy in AGC is only 15% to 24% [15]. The
response rate of 5-FU/platinum-based treatment is approximately
22% to 65% [16]. Cisplatin and 5-FU synergize with docetaxel. The
DCF regimen was first shown to have efficacy for the treatment of
patients with AGC in a multinational TAX-325 trial [17]. On the
basis of these results, docetaxel was approved in the United States andEurope for AGC. The role of the DCF regimen in the adjuvant
treatment of gastric cancer is not clear.
In this study, we show that the DCF regimen may also have a
survival benefit when used as adjuvant chemotherapy in gastric
cancer. The median DFS was 17 months, and the 2-year DFS rate
was 37.5%. According to the National Cancer Institute, Surveillance,
Epidemiology, and End Results Program (Bethesda, MD) database,
the 2-year survival rate was only 22% to 42% in patients with stage III
Figure 3.Median DFS and median OS by stage. A) Median DFS was 27.0 months in the stage I group, 25.0 months in the stage II group,
and 15.0 months in the stage III group (P = .660). B) Median OS was 29.0 months in the stage II group and 22.3 months in the stage III
group (P = .983).
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ACTS-GC and the CLASSIC trials. However, almost 70% of
patients enrolled in this study had AJCC stage III disease, which was
more advanced than the characteristics of those two trials. This
difference may influence survival times.
One controversial issue in the surgical management of gastric
cancer is the optimal extent of lymph node dissection. Some large
prospective clinical studies in western countries have shown that therewas no difference in the 5-year survival rate among patients who
underwent D1 versus D2 resection and that mortality related to
surgery was higher in the D2 group [19–21]. However, in Japan and
other Asian countries, clinical studies have shown that the D2
operation can reduce postoperative local recurrence rates compared
with D1 resection and that complication and operative mortality rates
are very low [22]. In this study, 22 patients (68.8%) received a D2
resection, and 10 patients (31.3%) underwent a D1 operation. The
Table 3. Adverse Events during Adjuvant Chemotherapy National Cancer Institute's Common
Terminology Criteria for Adverse Events v3.0 (NCI-CTC v3.0).
Grade 1/2 Grade 3/4 All Grades
n % n % n %
Hematology
Neutropenia 11 34.4% 18 56.3% 29 90.6%
Anemia 17 53.1% 0 0% 17 53.1%
Thrombocytopenia 8 25.0% 0 0% 8 25.0%
Febrile neutropenia 4 12.5% 0 0% 4 12.5%
Nonhematology
Liver function
ALT 9 28.1% 0 0% 9 28.1%
Tbil 9 28.1% 0 0% 9 28.1%
Gastrointestinal
Nausea 23 71.9% 2 6.3% 25 78.1%
Vomiting 16 50.0% 2 6.25% 18 56.3%
Stomatitis 4 12.5% 0 0% 4 12.5%
Diarrhea 8 25.0% 3 9.4% 11 34.4%
Constipation 6 18.8% 0 0% 6 18.8%
Peripheral neuropathy 5 15.6% 0 0% 5 15.6%
Arrhythmia 1 3.1% 0 0% 1 3.1%
Skin rash 3 9.4% 0 0% 3 9.4%
Fatigue 5 15.6% 0 0% 5 15.6%
ALT, Alanine aminotransferase; Tbil, total bilirubin.
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months for D1 and 18 months for D2 dissections; P = .043),
suggesting that D2 lymphadenectomy may provide a survival benefit.
This result may also suggest that patients who undergo a radical D2
dissection may also benefit more from adjuvant DCF chemotherapy.
For patients who have had a D1 resection, DCF adjuvant
chemotherapy may not be effective enough. The addition of
radiotherapy in these subgroups may be of paramount importance
on the basis of the results of the US Intergroup trial INT0116 [23]
and two recently published meta-analyses [24,25]. This study showed
that neutropenia and febrile neutropenia occurred most frequently in
patients treated with adjuvant DCF chemotherapy. The incidence of
grade 3/4 neutropenia was high (at 56.4%), and febrile neutropenia
occurred in 12.5% of patients. Other grade 3/4 adverse events
developed in less than 10% of patients. There were no chemotherapy-
related deaths in our study. The adverse events were manageable, and
nonhematologic AE were more tolerable than in some previous
studies. In TAX-325, the rates of any grade 3 or 4 toxicity during
therapy were high when triple therapy was used (81%), and the most
frequent grade 3/4 adverse events were neutropenia (30%) and
diarrhea (20%) [17].
In summary, our results support the use of combination
chemotherapy with DCF as a new approach to adjuvant treatment
in patients with gastric cancer who have undergone radical surgery.
We suggest further investigation of this adjuvant regimen.
Conflict of Interest
The authors report no conflicts of interest.
Acknowledgments
The authors thank all the patients who participated in this study.References
[1] Siegel R, Naishadham D, and Jemal A (2013). Cancer Statistics, 2013. CA
Cancer J Clin 63, 11–30.[2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2010).
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J
Cancer 127, 2893–2917.
[3] Yang L, Parkin DM, Li LD, Chen YD, and Bray F (2004). Estimation and
projection of the national profile of cancer mortality in China: 1991–2005. Br J
Cancer 90, 2157–2166.
[4] Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P,
Sakamoto J, Sargent D, and Sasako M, et al. (2010). Benefit of adjuvant
chemotherapy for resectable gastric cancer: ameta-analysis. JAMA303, 1729–1737.
[5] Sasako M, Saka M, Fukagawa T, Katai H, and Sano T (2007). Surgical treatment
of advanced gastric cancer: Japanese perspective. Dig Surg 24, 101–107.
[6] Hundahl SA, Phillips JL, and Menck HR (2000). The National Cancer Data
Base Report on poor survival of U.S. gastric carcinoma patients treated with
gastrectomy: Fifth Edition American Joint Committee on Cancer staging,
proximal disease, and the “different disease” hypothesis. Cancer 88, 921–932.
[7] Sun P, Xiang JB, and Chen ZY (2009). Meta-analysis of adjuvant chemotherapy
after radical surgery for advanced gastric cancer. Br J Surg 96, 26–33.
[8] Diaz-Nieto R, Orti-Rodríquez R, and Winslet M (2013). Post-surgical
chemotherapy versus surgery alone for resectable gastric cancer. Cochrane
Database Syst Rev 9, CD008415.
[9] Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T,
Nashimoto A, Fujii M, Nakajima T, and Ohashi Y (2011). Five-year outcomes of
a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus
surgery alone in stage II or III gastric cancer. J Clin Oncol 29, 4387–4393.
[10] Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH,
Noh SI, and Cho JY, et al. (2012). Adjuvant capecitabine and oxaliplatin for
gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label,
randomised controlled trial. Lancet 379, 315–321.
[11] Noh SH, Park SR, and Yang HK, et al. (2013). Adjuvant capecitabine and
oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: Final results of
the CLASSIC trial (abstract). 15th ESMO World Congress, Barcelona Spain;
2013.
[12] Lee J, Lim doH, Kim S, Park SH, Park JO, Park YS, LimHY, ChoiMG, SohnTS,
and Noh JH, et al. (2012). Phase III trial comparing capecitabine plus cisplatin
versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in
completely resected gastric cancer with D2 lymph node dissection: the ARTIST
trial. J Clin Oncol 30, 268–273.
[13] Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, and Iveson TJ, et al. (2006).
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med 355, 11–20.
[14] Lavelle F, Bissery MC, Combeau C, Riou JF, Vriqnaud P, and André S (1995).
Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22, 3–16.
[15] Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G,
Battelli N, and Cascinu S (2000). A phase II study of weekly docetaxel as salvage
chemotherapy for advanced gastric cancer. Ann Oncol 11, 1263–1266.
[16] Honecker F, Kollmannsberger C, Quietzsch D, Haaq C, Schroeder M, Spott C,
Hartmann JT, Baronius W, Hempel V, and Kanz L, et al. (2002). Phase II study
of weekly paclitaxel plus 24-h continuous infusion 5-flurouracil, folinci acid and
3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Anticancer Drugs 13, 497–503.
[17] Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C,
Rodrigues A, Fodor M, Chao Y, and Voznyi E, et al. (2007). Clinical benefit with
docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil
in a phase III trial of advanced gastric or gastroesophageal cancer adenocarci-
noma: the V-325 Study Group. J Clin Oncol 25, 3205–3209.
[18] Edge SB, Bzrd DR, and Compton CC (2010). American Joint Committee on
Cancer Staging Manual. 7th. New York: Springer; 2010. p. 117.
[19] Bonenkamp JJ, Songun 1Hermans J, SasakoM,Welvaart K, Plukker JT, van Elk P,
Obertop H, Gouma DJ, and Taat CW (1995). Randomised comparison of
morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.
Lancet 345, 745–748.
[20] Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, and Cook P,
Surgical Cooperative Group (1996). Postoperative morbidity and mortality after
Dl and D2 resections for gastric cancer:preliminary results of the MRC
randomised controlled surgical trial. Lancet 3(47), 995–999.
[21] Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M,
and Fayers P (1999). Patient survival after D1 and D2 resections for gastric
cancer: long-term results of the MRC randomised surgical trial. Surgical Co-
operative Group. Br J Cancer 79, 1522–1530.
Translational Oncology Vol. 7, No. 2, 2014 Chemotherapy for Gastric Cancer Meng et al. 283[22] Sano T, Katai H, SasakoM, andMaruyama K (2002). One thousand consecutive
gastrectomies without operative mortality. Br J Surg 89, 123.
[23] Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann
GN, Haller DG, Ajani JA, Gunderson LL, and Jessup JM, et al. (2001).
Chemoradiotherapy after surgery compared with surgery alone for adenocar-
cinoma of the stomach or gastroesephageal junction. N Engl J Med 345,
725–730.[24] Ohri N, Garg MK, Aparo S, Kaubisch A, TomeW, Kennedy TJ, Kalnicki S, and
Guha C (2013). Who benefits from adjuvant radiation therapy for gastric cancer?
A meta-analysis. Int J Radiat Oncol Biol Phys 86, 330–335.
[25] Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP,
and Du KL (2014). Chemoradiation therapy versus chemotherapy alone for
gastric cancer after R0 surgical resection: a meta-analysis of randomized trials.
Oncology 86, 79–85.
